Arcadium Lithium PLC to be removed from the S&P/ASX 200
Filed with ASX · · 2 pages · English
In the deck
Earlier from Mesoblast
- Ryoncil Pricing Set and Available This Quarter
- Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
- Dr. Gregory George MD PhD Joins Mesoblast Board
- Ryoncil Commercial Launch Update and Product Pipeline
- Mesoblast raises new capital for RYONCIL commercial launch
Later from Mesoblast
- Mesoblast Added to S&P/ASX 200 INDEX
- Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
- Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
- Ryoncil® is Now Available for Purchase in the United States
- First Three Children to Commence Treatment With Ryoncil®
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast